多發性骨髓瘤治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

2023 年，全球多發性骨髓瘤治療市場規模為 254 億美元，在多發性骨髓瘤發病率不斷上升以及治療方案大幅進步的推動下，2024 年至 2032 年將以 6.4% 的複合年成長率成長。意識的提高和診斷技術的改進導致了更早的發現和更高的病例報告。此外，標靶治療和免疫療法等創新療法的發展改變了患者的治療結果，提供了更有效和個人化的選擇。隨著醫療保健提供者採用這些進步以及越來越多的患者尋求治療，對多發性骨髓瘤治療的需求將繼續大幅成長。

多發性骨髓瘤治療行業根據治療類型、給藥途徑、疾病類型、最終用途和地區進行分類。

2023 年，標靶治療領域的銷售額達到 87 億美元，因為它能夠精確攻擊癌細胞，同時不傷害健康組織。這些療法包括單株抗體和蛋白酶體抑制劑，已證明在改善患者預後和延長存活率方面具有顯著療效。隨著正在進行的研究不斷揭示新的標靶和組合，標靶治療的吸引力必將增加。它們在臨床環境中的日益普及進一步鞏固了該細分市場在市場中的主導地位。

到 2032 年，醫院部分將擴大到 243 億美元，主要是因為它們作為癌症患者的初級治療中心。醫院提供全面的護理，包括先進的診斷工具、專門的治療方案以及多學科醫療保健專業人員團隊的幫助。隨著多發性骨髓瘤治療的複雜性增加，醫院設備精良，可以有效地管理和實施這些治療。此外，在醫院尋求治療的癌症患者數量不斷增加，進一步推動了這一領域的治療需求。

在先進的醫療基礎設施和高癌症診斷率的推動下，北美多發性骨髓瘤治療市場的複合年成長率將達到 6.2%，到 2032 年將達到 204 億美元。該地區受益於研發方面的大量投資，從而引入了創新療法。此外，人口老化的加劇和對多發性骨髓瘤認知的提高導致了更高的治療需求。進入專業醫療中心和全面的健康保險範圍進一步增加了患者獲得治療的機會，使北美成為全球市場的顯著貢獻者。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 多發性骨髓瘤盛行率增加
    • 改進的診斷技術
    • 患者意識和教育
  • 產業陷阱與挑戰
    • 治療費用高
    • 與治療相關的不良反應
• 成長潛力分析
• 監管環境
• 管道分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 化療
• 標靶治療
• 免疫調節劑
• 幹細胞移植
• 放射治療
• 其他治療類型

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

• 主要趨勢
• 口服
• 注射用

第 7 章：市場估計與預測：按疾病類型，2021 - 2032

• 主要趨勢
• 活動性多發性骨髓瘤
• 冒煙型多發性骨髓瘤

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院
• 專科診所
• 家庭護理設置
• 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• Service Provider
• Medication Manufacturers

The Global Multiple Myeloma Therapeutics Market held USD 25.4 billion in 2023 and will grow at 6.4% CAGR from 2024 to 2032, propelled by the increasing incidence of multiple myeloma, coupled with substantial advancements in treatment options. Rising awareness and improved diagnostic techniques have led to earlier detection and higher reported cases. Also, the development of innovative therapies, such as targeted treatments and immunotherapies, has transformed patient outcomes, providing more effective and personalized options. As healthcare providers adopt these advancements and more patients seek treatment, the demand for multiple myeloma therapeutics will continue to expand considerably.

The multiple myeloma therapeutics industry is divided based on treatment type, route of administration, disease type, end-use, and region.

The targeted therapy segment witnessed USD 8.7 billion in 2023, owing to its ability to precisely attack cancer cells while sparing healthy tissues. These therapies, which include monoclonal antibodies and proteasome inhibitors, have demonstrated significant efficacy in improving patient outcomes and prolonging survival rates. As ongoing research continues to unveil new targets and combinations, the appeal of targeted therapies is set to increase. Their rising adoption in clinical settings further solidifies this segment's dominant position in the market.

The hospitals segment will expand to USD 24.3 billion by 2032, primarily due to their role as primary treatment centers for cancer patients. Hospitals provide comprehensive care, including advanced diagnostic tools, specialized treatment regimens, and access to multidisciplinary teams of healthcare professionals. As the complexity of multiple myeloma therapies increases, hospitals are well-equipped to manage and administer these treatments effectively. Besides, the rising number of cancer patients seeking treatment in hospital settings further drives the demand for therapeutics in this segment.

North America multiple myeloma therapeutics market will demonstrate a 6.2% CAGR and register USD 20.4 billion by 2032, driven by advanced healthcare infrastructure and high rates of cancer diagnosis. The region benefits from sizable investments in research and development, leading to the introduction of innovative therapies. Furthermore, a growing aging population and increased awareness about multiple myeloma contribute to higher treatment demand. Access to specialized medical centers and comprehensive health insurance coverage further enhance patient access to therapies, making North America a notable contributor to the global market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of multiple myeloma
    • 3.2.1.2 Improved diagnostic technologies
    • 3.2.1.3 Patient awareness and education
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Adverse effects associated with treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Chemotherapy
• 5.3 Targeted therapy
• 5.4 Immunomodulating agents
• 5.5 Stem cell transplantation
• 5.6 Radiation therapy
• 5.7 Other treatment types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Active multiple myeloma
• 7.3 Smoldering multiple myeloma

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics
• 8.4 Homecare settings
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Service Provider
  • 10.1.1 Cleveland Clinic
  • 10.1.2 Dana-Farber Cancer Institute, Inc.
  • 10.1.3 Mayo Foundation for Medical Education and Research (MFMER)
  • 10.1.4 MD Anderson Cancer Center
  • 10.1.5 Memorial Sloan Kettering Cancer Center
• 10.2 Medication Manufacturers
  • 10.2.1 AbbVie Inc.
  • 10.2.2 Amgen Inc.
  • 10.2.3 Bristol-Myers Squibb Company.
  • 10.2.4 Glenmark Pharmaceuticals Ltd.
  • 10.2.5 Johnson and Johnson Services, Inc
  • 10.2.6 Merck and Co, Inc.
  • 10.2.7 Novartis AG
  • 10.2.8 Sanofi S.A.
  • 10.2.9 Takeda Pharmaceutical Company Limited